Randomized trial of rapamycin versus placebo for aging effects in older adults; safety and efficacy assessed
PEARL was a prospective, double-blind, placebo-controlled randomized trial examining rapamycin's safety and efficacy in reducing clinical measures of aging in older adults. The abstract does not report the sample size, which study arms were compared, what outcome measures were used, or what effects were observed.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jan 24, 2024 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Healthy older adult population
- Primary outcome
- Safety and efficacy in reducing clinical measures of aging
- Effect size
- —
- Significance
- Not reported
- Journal
- AgelessRx
- Published
- Jan 24, 2024
Sources
Primary source
- AgelessRx ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.